Question 2 of 6 Fundamentals Concept
What would you check before concluding a cytokine increased T-cell activation?
Short answer
Confirm that the cytokine changed T-cell behavior rather than simply cell survival, subset composition or background staining. Compare matched control and treated cultures, measure viable T-cell counts and use independent activation and functional readouts over an appropriate time course.
Why
A single rise in CD69 or a secreted cytokine is not automatically proof of a stronger antigen-specific T-cell response. Define the proposed mechanism: direct cytokine signaling, improved TCR costimulation or altered antigen-presenting cells. Run vehicle or medium controls, measure viability and absolute live T-cell numbers, and distinguish CD4, CD8 and relevant memory subsets.
Test activation-associated markers at suitable early time points and assess later proliferation or function separately. For example, a treatment might increase the percentage of CD69-positive T cells because resting cells died, leaving an enriched activated subset without increasing the number of activated cells. Include a functional positive control and, when claiming antigen specificity, irrelevant peptide or no-antigen stimulation alongside cognate antigen.
Check whether other cell types in the culture produce the measured cytokine. If feasible, confirm pathway engagement with an orthogonal assay. Report denominator, timing and donor-level replication instead of relying only on one fluorescence shift.
Common mistakes
- Interpreting a higher percentage of CD69-positive cells as de novo activation without checking absolute counts and viability
The interviewer might ask next
How would you distinguish improved T-cell activation from selective survival of activated cells?